88 related articles for article (PubMed ID: 23808961)
1. Treatment patterns and outcomes in patients with advanced melanoma in France.
Bedane C; Leccia MT; Sassolas B; Bregman B; Lebbé C;
Curr Med Res Opin; 2013 Oct; 29(10):1297-305. PubMed ID: 23808961
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).
Lebbe C; Lorigan P; Ascierto P; Testori A; Bédane C; Middleton M; van Baardewijk M; Konto C; Dueymes A; Maio M
Eur J Cancer; 2012 Nov; 48(17):3205-14. PubMed ID: 22742880
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
4. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
[TBL] [Abstract][Full Text] [Related]
6. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
7. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
[TBL] [Abstract][Full Text] [Related]
8. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
Fink W; Zimpfer-Rechner C; Thoelke A; Figl R; Kaatz M; Ugurel S; Schadendorf D
Onkologie; 2004 Dec; 27(6):540-4. PubMed ID: 15591712
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
Gonsalves CF; Eschelman DJ; Sullivan KL; Anne PR; Doyle L; Sato T
AJR Am J Roentgenol; 2011 Feb; 196(2):468-73. PubMed ID: 21257902
[TBL] [Abstract][Full Text] [Related]
12. Management and outcome of metastatic melanoma during pregnancy.
Pagès C; Robert C; Thomas L; Maubec E; Sassolas B; Granel-Brocard F; Chevreau C; De Raucourt S; Leccia MT; Fichet D; Khammari A; Boitier F; Stoebner PE; Dalac S; Celerier P; Aubin F; Viguier M
Br J Dermatol; 2010 Feb; 162(2):274-81. PubMed ID: 19804595
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
14. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
19. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
